News & Updates

Show Multimedia Only

Optimizing prostate cancer outcomes with 177Lu-PSMA-617 radioligand therapy

22 Apr 2026 by

Radioligand therapy, which uses prostate-specific membrane antigen (PSMA)–targeted agents to deliver tumour‑focused radiation, has become a key treatment for metastatic castration‑resistant prostate cancer (mCRPC). At an industry‑sponsored meeting, Professor Kim-Nguyen Chi of the University of British Columbia in Vancouver, Canada, discussed how PSMA-targeted radioligand therapy, specifically lutetium 177–PSMA 617 (¹⁷⁷Lu-PSMA-617), is reshaping mCRPC management and optimizes outcomes.

Optimizing prostate cancer outcomes with 177Lu-PSMA-617 radioligand therapy

22 Apr 2026

Complete response to durvalumab consolidation in a patient with unresectable stage III PD-L1–negative NSCLC

15 Apr 2026 by

A 60-year-old nonsmoking female presented with mild cough in 2023. Apart from hypertension and a history of lung cancer in her father, she was physically fit with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0.

Complete response to durvalumab consolidation in a patient with unresectable stage III PD-L1–negative NSCLC

15 Apr 2026

[Infographics] Slow down lung function decline in CTD-ILD with nintedanib

14 Apr 2026

Nintedanib is the only antifibrotic approved in Hong Kong for progressive pulmonary fibrosis and systemic sclerosis–associated interstitial lung disease (ILD). Read further on how nintedanib slows lung function decline in connective tissue disease–associated ILD (CTD-ILD), as well as ERS/EULAR 2025 guideline recommendations on screening, diagnosis, monitoring, and treatment of CTD-ILD.

[Infographics] Slow down lung function decline in CTD-ILD with nintedanib

14 Apr 2026

[Infographics] 2026 ASA Practice Guideline: Fascial plane blocks as essential components of perioperative pain management

14 Apr 2026

The 2026 ASA Practice Guideline provides strong recommendations with moderate-strength evidence for FPBs as essential components of perioperative pain management across open cardiothoracic, abdominal, retroperitoneal, pelvic surgeries, mastectomy, and minimally invasive abdominal procedures.

[Infographics] 2026 ASA Practice Guideline: Fascial plane blocks as essential components of perioperative pain management

14 Apr 2026

Managing chronic-phase CML: From intolerance to resistance – clinical experience with asciminib in HK

11 Apr 2026 by

Case 1: A 78-year-old male with pre-existing comorbidities, including diabetes, hypertension and ischaemic heart disease (IHD), exemplified the real-world challenges of long-term tyrosine kinase inhibitor (TKI) therapy in chronic myeloid leukaemia (CML). Case 2: A 66-year-old male with a long-standing history of CML and failure of multiple TKIs had restored molecular control after switching to a TKI that specifically targets the ABL myristoyl pocket (STAMP).

Managing chronic-phase CML: From intolerance to resistance – clinical experience with asciminib in HK

11 Apr 2026

Topical ruxolitinib for vitiligo repigmentation demonstrates long-term efficacy, including in Chinese patients

10 Apr 2026 by

Ruxolitinib 1.5 percent cream is the first topical repigmentation treatment approved by the US FDA, European Medicines Agency and in Hong Kong, as well as several other countries, for use in patients ≥12 years of age with nonsegmental vitiligo with facial involvement. Professor Henry Lim of the Department of Dermatology, Henry Ford Health, Detroit, Michigan, US, and Professor Yanhua Liang of the Department of Dermatology, Cosmetology and Venereology, Shenzhen Hospital of Southern Medical University, Shenzhen, China, shared their experience of treating vitiligo with ruxolinitib at the Global Chinese Dermatology Summit held recently in Hong Kong.

Topical ruxolitinib for vitiligo repigmentation demonstrates long-term efficacy, including in Chinese patients

10 Apr 2026

TKOH’s HF programme reduces rehospitalizations and improves outcomes

10 Apr 2026 by

In Hong Kong, heart failure (HF) is a leading cause of hospitalization with a high readmission rate. Improved HF management models are needed to ensure continuous patient monitoring and rapid uptitration of guideline-directed medical therapy (GDMT). In an interview with MIMS Doctor, Dr Shun-Hei Wong, Specialist in Cardiology at Tseung Kwan O Hospital (TKOH), shared details of TKOH’s new HF management programme, which has notably reduced readmissions and improved functional capacity and other outcomes in patients with acute HF.

TKOH’s HF programme reduces rehospitalizations and improves outcomes

10 Apr 2026

Use of sotatercept in a patient with connective tissue disease–related PAH on triple therapy

08 Apr 2026 by

A 61-year-old female with a >20-year history of connective tissue disease–related pulmonary arterial hypertension (CTD-PAH) was admitted in June 2025. Despite being on triple therapy for PAH as well as prednisolone and cyclophosphamide for systemic lupus erythematosus (SLE), her PAH remained uncontrolled.

Use of sotatercept in a patient with connective tissue disease–related PAH on triple therapy

08 Apr 2026

First-line panitumumab improves metastatic-site resection rates in RAS wild-type mCRC

02 Apr 2026

At the European Society for Medical Oncology (ESMO) Asia Congress 2025 in Singapore, results of a retrospective cohort study that evaluated first-line panitumumab- vs cetuximab-based therapy in patients with newly diagnosed RAS wild-type metastatic colorectal cancer (mCRC) were reported. The analysis focused on overall survival (OS) and metastatic-site resection rates, providing valuable real-world insights into treatment selection beyond traditional survival endpoints.

First-line panitumumab improves metastatic-site resection rates in RAS wild-type mCRC

02 Apr 2026

Real-world data reaffirm RSVpreF vaccine’s benefit in older individuals

31 Mar 2026

Along with its efficacy established in the pivotal RENOIR trial, real-world studies published more recently continue to demonstrate effectiveness of the bivalent respiratory syncytial virus (RSV) prefusion F protein–based (RSVpreF) vaccine in protecting against RSV-associated outcomes in older individuals aged ≥60 years.

Real-world data reaffirm RSVpreF vaccine’s benefit in older individuals

31 Mar 2026

News & Updates

Showing Multidisciplinary articles

Showing

Specialty:

Optimizing prostate cancer outcomes with 177Lu-PSMA-617 radioligand therapy

Optimizing prostate cancer outcomes with 177Lu-PSMA-617 radioligand therapy

Complete response to durvalumab consolidation in a patient with unresectable stage III PD-L1–negative NSCLC

Complete response to durvalumab consolidation in a patient with unresectable stage III PD-L1–negative NSCLC

[Infographics] Slow down lung function decline in CTD-ILD with nintedanib

[Infographics] Slow down lung function decline in CTD-ILD with nintedanib

[Infographics] 2026 ASA Practice Guideline: Fascial plane blocks as essential components of perioperative pain management

[Infographics] 2026 ASA Practice Guideline: Fascial plane blocks as essential components of perioperative pain management

Managing chronic-phase CML: From intolerance to resistance – clinical experience with asciminib in HK

Managing chronic-phase CML: From intolerance to resistance – clinical experience with asciminib in HK

Topical ruxolitinib for vitiligo repigmentation demonstrates long-term efficacy, including in Chinese patients

Topical ruxolitinib for vitiligo repigmentation demonstrates long-term efficacy, including in Chinese patients

TKOH’s HF programme reduces rehospitalizations and improves outcomes

TKOH’s HF programme reduces rehospitalizations and improves outcomes

Use of sotatercept in a patient with connective tissue disease–related PAH on triple therapy

Use of sotatercept in a patient with connective tissue disease–related PAH on triple therapy

First-line panitumumab improves metastatic-site resection rates in RAS wild-type mCRC

First-line panitumumab improves metastatic-site resection rates in RAS wild-type mCRC

Real-world data reaffirm RSVpreF vaccine’s benefit in older individuals

Real-world data reaffirm RSVpreF vaccine’s benefit in older individuals